Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.17 -1.3%	$1.35	$0.86 ▼ $3.78	$254.82M	0.6	3.32 million shs	3.02 million shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
INDV Indivior	$12.72 +2.5%	$10.49	$7.33 ▼ $18.59	$1.75B	0.98	1.04 million shs	2.16 million shs
OCUL Ocular Therapeutix	$8.01 -1.6%	$7.37	$4.79 ▼ $11.78	$1.28B	1.51	1.41 million shs	2.18 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-1.27%	+9.91%	-30.65%	-40.26%	-50.00%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+5.43%
INDV Indivior	+2.50%	+12.97%	+10.51%	+37.66%	-29.49%
OCUL Ocular Therapeutix	-1.60%	+9.73%	-3.49%	+12.18%	+36.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.7491 of 5 stars	4.5	3.0	0.0	2.7	3.3	0.6
CALT Calliditas Therapeutics AB (publ)	0.0698 of 5 stars	1.0	0.0	0.0	0.0	0.0	0.6
INDV Indivior	2.5589 of 5 stars	2.6	3.0	0.0	2.6	1.7	1.9
OCUL Ocular Therapeutix	3.658 of 5 stars	3.4	1.0	4.1	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	624.85% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
INDV Indivior	3.25	Buy	$15.00	17.92% Upside
OCUL Ocular Therapeutix	2.88	Moderate Buy	$16.25	102.87% Upside

Current Analyst Ratings Breakdown

Latest ALLO, INDV, OCUL, and CALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	11,582.80	N/A	N/A	$3.04 per share	0.38
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
INDV Indivior	$1.17B	1.50	$2.57 per share	4.94	N/A	∞
OCUL Ocular Therapeutix	$59.65M	21.39	N/A	N/A	$0.79 per share	10.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.23	N/A	N/A	N/A	N/A	-52.13%	-41.29%	8/6/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
INDV Indivior	$2M	-$0.31	N/A	7.44	N/A	-3.96%	-241.73%	15.09%	7/24/2025 (Estimated)
OCUL Ocular Therapeutix	-$80.74M	-$1.15	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	8/6/2025 (Estimated)

Latest ALLO, INDV, OCUL, and CALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million
3/13/2025	Q4 2024	ALLO Allogene Therapeutics	-$0.34	-$0.28	+$0.06	-$0.28	$0.01 million	N/A
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
INDV Indivior	N/A	0.83	0.65
OCUL Ocular Therapeutix	0.19	13.01	12.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CALT Calliditas Therapeutics AB (publ)	2.83%
INDV Indivior	60.33%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CALT Calliditas Therapeutics AB (publ)	2.20%
INDV Indivior	N/A
OCUL Ocular Therapeutix	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	158.72 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
OCUL Ocular Therapeutix	230	159.30 million	151.71 million	Optionable

ALLO, INDV, OCUL, and CALT Headlines

Recent News About These Companies

Voloridge Investment Management LLC Has $286,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 31 at 4:10 AM | marketbeat.com

Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 31 at 3:37 AM | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE

May 31 at 3:13 AM | marketbeat.com

Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at HC Wainwright

May 30 at 12:31 PM | marketbeat.com

Ocular Therapeutix's (OCUL) Buy Rating Reiterated at HC Wainwright

May 30 at 3:09 AM | americanbankingnews.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sanjay Nayak Sells 1,862 Shares

May 29 at 8:08 PM | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Peter Kaiser Sells 2,974 Shares

May 29 at 8:08 PM | marketbeat.com

Insider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 3,024 Shares of Stock

May 29 at 8:08 PM | marketbeat.com

Pravin Dugel Sells 21,219 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

May 29 at 8:07 PM | marketbeat.com

Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews

May 29 at 4:34 PM | benzinga.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Down 4.8% - Here's What Happened

May 29 at 4:16 PM | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Trading Up 5.4% - Still a Buy?

May 29 at 12:42 PM | marketbeat.com

Ocular Therapeutix chief scientific officer sells $21,712 in stock

May 29 at 11:33 AM | investing.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Polar Asset Management Partners Inc.

May 28 at 5:52 AM | marketbeat.com

Insider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 1,862 Shares of Stock

May 28 at 5:46 AM | insidertrades.com

BNP Paribas Financial Markets Acquires 39,599 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 26, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Brokerages

May 23, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Deutsche Bank AG

May 22, 2025 | marketbeat.com

Ocular Therapeutix at RBC Conference: Strategic Advancements in Wet AMD Trials

May 21, 2025 | uk.investing.com

Graham Capital Management L.P. Takes $321,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 20, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Second Line Capital LLC

May 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Super Micro Computer Stock Clears New Path Higher on Saudi Orders
By Gabriel Osorio-Mazilli | May 22, 2025
View Super Micro Computer Stock Clears New Path Higher on Saudi Orders
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
By Leo Miller | May 6, 2025
View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

ALLO, INDV, OCUL, and CALT Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.16 -0.02 (-1.27%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.18 +0.01 (+1.29%)

As of 05/30/2025 07:24 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 05/29/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Indivior NASDAQ:INDV

$12.72 +0.31 (+2.50%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$12.86 +0.14 (+1.06%)

As of 05/30/2025 07:52 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Ocular Therapeutix NASDAQ:OCUL

$8.01 -0.13 (-1.60%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$8.04 +0.03 (+0.36%)

As of 05/30/2025 05:55 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time